JP2004528332A5 - - Google Patents

Download PDF

Info

Publication number
JP2004528332A5
JP2004528332A5 JP2002582954A JP2002582954A JP2004528332A5 JP 2004528332 A5 JP2004528332 A5 JP 2004528332A5 JP 2002582954 A JP2002582954 A JP 2002582954A JP 2002582954 A JP2002582954 A JP 2002582954A JP 2004528332 A5 JP2004528332 A5 JP 2004528332A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
polymer
uric acid
crosslinking agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002582954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/011492 external-priority patent/WO2002085381A1/en
Publication of JP2004528332A publication Critical patent/JP2004528332A/ja
Publication of JP2004528332A5 publication Critical patent/JP2004528332A5/ja
Pending legal-status Critical Current

Links

JP2002582954A 2001-04-18 2002-04-10 痛風を治療する方法および尿酸を結合する方法 Pending JP2004528332A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US30556701P 2001-07-13 2001-07-13
PCT/US2002/011492 WO2002085381A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Publications (2)

Publication Number Publication Date
JP2004528332A JP2004528332A (ja) 2004-09-16
JP2004528332A5 true JP2004528332A5 (https=) 2005-12-22

Family

ID=26962624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582954A Pending JP2004528332A (ja) 2001-04-18 2002-04-10 痛風を治療する方法および尿酸を結合する方法

Country Status (9)

Country Link
US (2) US20030039627A1 (https=)
EP (1) EP1416942B1 (https=)
JP (1) JP2004528332A (https=)
AT (1) ATE380553T1 (https=)
BR (1) BR0209133A (https=)
CA (1) CA2444347A1 (https=)
DE (1) DE60224052T2 (https=)
MX (1) MXPA03009571A (https=)
WO (1) WO2002085381A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
WO2004037274A1 (en) * 2002-10-22 2004-05-06 Genzyme Corporation Amine polymers for promoting bone formation
WO2004099288A1 (en) * 2003-05-09 2004-11-18 Carlsberg A/S Polyethyleneimine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
HUE026628T2 (en) 2005-09-15 2016-06-28 Genzyme Corp Pouches for amine polymers
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
EP2016114A2 (en) * 2006-05-05 2009-01-21 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
EP2043627A2 (en) * 2006-07-05 2009-04-08 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US20100124542A1 (en) * 2006-07-18 2010-05-20 Genzyme Corporation Amine dendrimers
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
US8163799B2 (en) * 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
CN101646440A (zh) * 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
JP2010519298A (ja) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
JP2010520285A (ja) * 2007-03-08 2010-06-10 ゲンズイメ コーポレーション スルホンポリマー組成物
US20100166696A1 (en) * 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
EP2217215A1 (en) * 2007-12-14 2010-08-18 Genzyme Corporation Coated pharmaceutical compositions
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
EP3003327B1 (en) 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
RS61409B1 (sr) 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
EP3564292B1 (en) 2016-12-28 2021-06-16 FUJIFILM Corporation Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
WO2023023938A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4164659B1 (en) * 2021-08-24 2024-03-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271191A (en) * 1979-12-19 1981-06-02 Pierre Fabre S.A. Method of treating hyperuricemia and gout
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
NZ335329A (en) * 1996-10-23 2001-06-29 Dow Chemical Co Water soluble polyether glycol polymer capable of complexing phosphate or oxalate used for reduction of dietary phosphate or oxalate absorption
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid

Similar Documents

Publication Publication Date Title
JP2004528332A5 (https=)
JP2004535384A5 (https=)
JP2001521902A5 (https=)
JP2007517047A5 (https=)
CA2444046A1 (en) Use of colesevelam in reducing serum glucose
JP2004516314A5 (https=)
JP2024119812A5 (https=)
JP2009534470A5 (https=)
CA2481365A1 (en) Occlusive composition comprising a poly (2-cyanoacrylate) monomer
JP2004531544A5 (https=)
JP2005538035A5 (https=)
JP2022548052A5 (https=)
JP2004520473A5 (https=)
CN104548193A (zh) 具有含不同水胶体成分的粘合剂层的分层粘合剂结构
JP2006526563A5 (https=)
JP2005506298A5 (https=)
JP2002501049A5 (https=)
JP2001526218A5 (https=)
JP2004526778A5 (https=)
JP2011515349A5 (https=)
JPH10192285A5 (https=)
JP2019211764A5 (https=)
RU2010153904A (ru) Ниацин-содержащие композиции с модифицированным высвобождением
JP2020518685A5 (https=)
EP1238654A3 (en) Composition for external application containing a diamide derivative